Metabolism of glioma and IDH1/IDH2 mutations

Revue Neurologique

Volumn 167, Issue 10, 2011, Pages 699-703

  Rossetto, M ^a   Ciccarino, P ^a   Boisselier, B ^a   Labussiere, M ^a   Sanson, M ^a,b  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

2 hydroxyglutarate; Glioma; IDH1; IDH2; Prognostic markers

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; ISOCITRATE DEHYDROGENASE (NADP); ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC CODE; GLIOBLASTOMA; GLIOMA; SEQUENCE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 81955160750     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2011.08.002     Document Type: Article

References (36)

1. M. Aghili, F. Zahedi, and E. Rafiee Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review J Neurooncol 91 2 2009 233 236
2. M.F. Amary, K. Bacsi, F. Maggiani, S. Damato, D. Halai, and F. Berisha IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumors J Pathol 224 3 2011 334 343
3. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 6 2008 597 602
4. F.E. Bleeker, N.A. Atai, S. Lamba, A. Jonker, D. Rijkeboer, and K.S. Bosch The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma Acta Neuropathol 119 4 2011 487 494
5. F.E. Bleeker, S. Lamba, S. Leenstra, D. Troost, T. Hulsebos, and W.P. Vandertop IDH1 mutations at residue p.R132 (IDH1[R132]) occur frequently in high-grade gliomas but not in other solid tumors Hum Mutat 30 1 2009 7 11
6. R.A. Cairns, I.S. Harris, and T.W. Mak Regulation of cancer cell metabolism Nat Rev Cancer 11 2 2011 85 95
7. D. Capper, S. Weissert, J. Balss, A. Habel, J. Meyer, and D. Jager Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors Brain Pathol 20 1 2010 245 254
8. L. Dang, D.W. White, F. Gross, B.D. Bennett, M.A. Bittinger, and E.M. Driggers Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 7274 2009 739 744
9. H.J. Dubbink, W. Taal, R. van Marion, J.M. Kros, I. van Heuvel, and J.E. Bromberg IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 21 2009 1792 1795
10. F. Ducray, S. El Hallani, and A. Idbaih Diagnostic and prognostic markers in gliomas Curr Opin Oncol 21 6 2009 537 542
11. F. Ducray, Y. Marie, and M. Sanson IDH1 and IDH2 mutations in gliomas N Engl J Med 360 21 2009 2248 [author reply 2249]
12. M.E. Figueroa, O. Abdel-Wahab, C. Lu, P.S. Ward, J. Patel, and A. Shih Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 6 2010 553 567
13. S. Gross, R.A. Cairns, M.D. Minden, E.M. Driggers, M.A. Bittinger, and H.G. Jang Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations J Exp Med 207 2 2010 339 344
14. C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, R. Guillevin, and J. Laffaire IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 17 2010 1560 1566
15. K. Ichimura, D.M. Pearson, S. Kocialkowski, L.M. Backlund, R. Chan, and D.T. Jones IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas Neuro Oncol 11 4 2009 341 347
16. M.R. Kang, M.S. Kim, J.E. Oh, Y.R. Kim, S.Y. Song, and S.I. Seo Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers Int J Cancer 125 2 2009 353 355
17. Y. Kato, G. Jin, C.T. Kuan, R.E. McLendon, H. Yan, and D.D. Bigner A monoclonal antibody IMab-1 specifically recognizes IDH1-R132H, the most common glioma-derived mutation Biochem Biophys Res Commun 390 3 2009 547 551
18. M. Labussiere, A. Idbaih, X.W. Wang, Y. Marie, B. Boisselier, and C. Falet All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 23 2010 1886 1890
19. A. Latini, K. Scussiato, R.B. Rosa, G. Leipnitz, S. Llesuy, and A. Belló-Klein Induction of oxidative stress by L-2-hydroxyglutaric acid in rat brain J Neurosci Res 74 1 2003 103 110 (Pubitemid 37176673)
20. G. Marcucci, K. Maharry, Y.Z. Wu, M.D. Radmacher, K. Mrozek, and D. Margeson IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study J Clin Oncol 28 14 2010 2348 2355
21. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009:NEJMoa0903840.
22. E.D. Michelakis, G. Sutendra, P. Dromparis, L. Webster, A. Haromy, and E. Niven Metabolic modulation of glioblastoma with dichloroacetate Sci Trans Med 2 31 2010 31 34
23. S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 19 2009 6002 6007
24. H. Noushmehr, D.J. Weisenberger, K. Diefes, H.S. Phillips, K. Pujara, and B.P. Berman Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 5 2010 510 522
25. D.W. Parsons, S. Jones, X. Zhang, J.C. Lin, R.J. Leary, and P. Angenendt An integrated genomic analysis of human glioblastoma multiforme Science 321 5897 2008 1807 1812
26. Z.J. Reitman, G. Jin, E.D. Karoly, I. Spasojevic, J. Yang, and K.W. Kinzler Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome Proc Natl Acad Sci U S A 108 8 2011 3270 3275
27. M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, and F. Ducray Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 25 2009 4150 4154
28. M.J. Seltzer, B.D. Bennett, A.D. Joshi, P. Gao, A.G. Thomas, and D.V. Ferraris Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1 Cancer Res 70 22 2010 8981 8987
29. M.J. van den Bent, H.J. Dubbink, Y. Marie, A.A. Brandes, M.J. Taphoorn, and P. Wesseling IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the european organization for research and treatment of Cancer Brain Tumor Group Clin Cancer Res 16 5 2010 1597 1604
30. R.G. Verhaak, K.A. Hoadley, E. Purdom, V. Wang, Y. Qi, and M.D. Wilkerson Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 1 2010 98 110
31. P.S. Ward, J. Patel, D.R. Wise, O. Abdel-Wahab, B.D. Bennett, and H.A. Coller The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 3 2010 225 234
32. T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 4 2009 1149 1153
33. W. Wick, C. Hartmann, C. Engel, M. Stoffels, J. Felsberg, and F. Stockhammer NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 35 2009 5874 5880
34. W. Xu, H. Yang, Y. Liu, Y. Yang, P. Wang, and S.H. Kim Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate dependent dioxygenases Cancer Cell 19 1 2011 17 30
35. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, and W. Yuan IDH1 and IDH2 mutations in gliomas N Engl J Med 360 8 2009 765 773
36. S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, and P. Wang Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha Science 324 5924 2009 261 265